Upon the completion of this trial, many of the patients had a reduction in autophagy activity and PCNA proliferation index in DCIS lesions [267], implying a decreased rate of invasion and metastasis [268]. The gene discussed is PCNA; the disease is ductal breast carcinoma in situ.